Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.
about
Fluphenazine decanoate (depot) and enanthate for schizophreniaMaintenance treatment with antipsychotic drugs for schizophreniaFluphenazine (oral) versus placebo for schizophreniaFluphenazine (oral) versus placebo for schizophreniaDepot fluphenazine decanoate and enanthate for schizophreniaSubjective response to antipsychotic treatment and compliance in schizophrenia. A naturalistic study comparing olanzapine, risperidone and haloperidol (EFESO Study)Comparison of SGA oral medications and a long-acting injectable SGA: the PROACTIVE studyProfile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a reviewHealth care reform and rural mental health: severe mental illness.Long-acting paliperidone palmitate - interim results of an observational study of its effect on hospitalization.Depot neuroleptics, schizophrenia and the role of the nurse: is practice evidence based? A review of the literature.Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Unanswered questions in schizophrenia clinical trialsPredictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind studyPoor response to treatment: beyond medication.Validation of the German Version of the Social Functioning Scale (SFS) for schizophrenia.Neuropsychiatric rehabilitation for persistent mental illness.The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.Outpatient Follow-Up Visit after Hospital Discharge Lowers Risk of Rehospitalization in Patients with Schizophrenia: A Nationwide Population-Based StudyAssociation between Medication Adherence and Duration of Outpatient Treatment in Patients with SchizophreniaPsychosocial treatments to promote functional recovery in schizophreniaTactics and technologies to manage nonadherence in patients with schizophrenia.Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review.Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.Treatment adherence and social functioning in patients diagnosed with schizophrenia and treated with antipsychotic depot medication.Collaboration with families for the rehabilitation of schizophrenic patients and the concept of expressed emotion.Survival analysis (or time to an event analysis), and the Cox regression model--methods for longitudinal psychiatric research.Predictors of burden among lower socioeconomic status caregivers of persons with chronic mental illness.Review: treatment of schizophrenia. State of the art.[Who are the patients treated in an outpatient clinic with high dosage neuroleptics?]The history of the psychopharmacology of schizophrenia.Group therapy with schizophrenic patients in outpatient departments.Patient perspectives in the development and use of long-acting antipsychotics in schizophrenia: focus on olanzapine long-acting injection.Challenges in the design and conduct of controlled clinical effectiveness trials in schizophrenia.Psychosocial factors in the cause and prevention of relapse in schizophrenia.Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia.Long-term observation of patients successfully switched to risperidone long-acting injectable: A retrospective, naturalistic 18-month mirror-image study of hospitalization rates and therapy costs.
P2860
Q24188205-DEE2A190-30F2-4BC8-BEB6-2729288CDCFBQ24197902-6A0A883A-3599-43FC-B739-79B243176095Q24201157-E2A96DD2-6893-493C-96DD-A7A95A12AD53Q24243129-33EEA0DC-5701-42EE-9317-041ED89559D3Q24247121-809B6D0A-745D-40E7-BC4E-211727148032Q24801695-9337D7ED-62EF-4B00-A5CC-2725D3C288CBQ27320151-CA041AC3-8DF2-4EC6-80AD-39BEA596744CQ28084899-DBB5B8B6-8857-4631-9482-F4140CFDCFF9Q30469535-8E19907B-3BE9-45F8-A044-C15070F33B78Q33718170-5579487D-8425-4DF0-A342-AC89710FCD6AQ33785814-6C3D4E18-E8D1-419E-8D65-87F5893BE3EDQ34293899-47F835B4-FC4B-4874-A143-DFA8EDEF7E44Q34418847-3FA92004-4167-4A26-9C0A-B3171CBB08D3Q34587166-260940ED-FE84-4702-88FA-FF9E80752163Q34990923-86FABC81-BB83-4DDA-A580-FE1DBFBA0C31Q35236765-5223F32A-DA7A-413B-BCE5-BFFB2F408CACQ35250883-A63AD270-757F-4E52-ADFC-8DC66108787CQ35531500-96E21A7D-EBF1-48DB-83CE-28B93A8A98ECQ36059843-391F7D40-F9FB-46A9-A4BD-4FC670204412Q36205371-13F1EE85-C320-4ECE-84B2-B71BE0ACAF34Q37136984-5AD76ECC-FA64-4044-A2A5-CACEBDD3F68BQ37137030-430CC4A0-DAA9-4DDE-B7A5-535EA587FF26Q37216925-DE603CDC-0F4A-44C7-9BA0-5B873E644793Q37451403-A4A285EB-094D-4A68-8D25-045779B21308Q38042430-3385D133-9EC5-43B8-92CE-564B326FBD7FQ38064842-E8BD6C2F-CE11-4945-B4DF-3CB68D7E65B1Q38363963-76CC1793-FF4D-400F-9D6D-B3C208CE1320Q38451320-9E81E6AF-B1B0-42CA-ACB3-0C2F30E77393Q38647152-0C656CFF-C178-47A6-9889-1CEE7402C3CAQ39760068-15DC8155-139B-499A-A5E0-8B12BA30DDEBQ41017386-52F06FAC-D983-4B50-A9A6-58ABFFDDE903Q41156710-0D89EBFE-3BEF-4D80-95A7-FD7EA7118029Q41173472-EECBB187-3A92-4286-AE6D-620EB5ABC9CAQ41380354-59E7620B-E24B-41F2-B95F-AA0F85B22735Q41973776-80D690A0-AA5C-42B1-817B-4F7AE3322E89Q42279135-73515229-9E50-4EFF-AD44-B615EC20DCCEQ42687642-0948B66B-119A-4A69-B480-92111DEB739AQ42782375-39DDA88A-21E4-4003-8645-6B6B800E4033Q43273757-6B94F2CD-9EF9-4F68-B7D4-C2C967FA089CQ44288030-30C29FDD-07F7-4927-AA45-93FD7815CD37
P2860
Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride.
description
1979 nî lūn-bûn
@nan
1979年の論文
@ja
1979年論文
@yue
1979年論文
@zh-hant
1979年論文
@zh-hk
1979年論文
@zh-mo
1979年論文
@zh-tw
1979年论文
@wuu
1979年论文
@zh
1979年论文
@zh-cn
name
Fluphenazine and social therap ...... nd fluphenazine hydrochloride.
@en
type
label
Fluphenazine and social therap ...... nd fluphenazine hydrochloride.
@en
prefLabel
Fluphenazine and social therap ...... nd fluphenazine hydrochloride.
@en
P2093
P1433
P1476
Fluphenazine and social therap ...... nd fluphenazine hydrochloride.
@en
P2093
P304
P356
10.1001/ARCHPSYC.1979.01780120013001
P407
P577
1979-11-01T00:00:00Z